Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice

Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab 292: E238-E245, 2007. First published August 29, 2006; doi:10.1152/ajpendo.00239.2006. PYY3-36 is a gut-derived hormone acting on hypothalamic nuclei to inhibit food intake. We recently showed that PYY3-36 acutely reinforces insulin action on glucose disposal in mice. We aimed to evaluate effects of PYY3-36 on energy metabolism and the impact of chronic PYY3-36 treatment on insulin sensitivity. Mice received a single injection of PYY3-36 or were injected once daily for 7 days, and energy metabolism was subsequently measured in a metabolic cage. Furthermore, the effects of chronic PYY3-36 administration (continuous and intermittent) on glucose turnover were determined during a hyperinsulinemic-euglycemic clamp. PYY3-36 inhibited cumulative food intake for 30 min of refeeding after an overnight fast (0.29 +/- 0.04 vs. 0.56 +/- 0.12 g, P = 0.036) in an acute setting, but not after 7 days of daily dosing. Body weight, total energy expenditure, and physical activity were not affected by PYY3-36. However, it significantly decreased the respiratory quotient. Both continuous and intermittent PYY3-36 treatment significantly enhanced insulin-mediated whole body glucose disposal compared with vehicle treatment (81.2 +/- 6.2 vs. 77.1 +/- 5.2 vs. 63.4 +/- 5.5 mu mol.min(-1).kg(-1), respectively). In particular, PYY3-36 treatment increased glucose uptake in adipose tissue, whereas its impact on glucose disposal in muscle did not attain statistical significance. PYY3-36 treatment shifts the balance of fuel use in favor of fatty acids and enhances insulin sensitivity in mice, where it particularly promotes insulin-mediated glucose disposal. Notably, these metabolic effects of PYY3-36 remain unabated after chronic administration, in contrast to its anorexic effects.